Profound® Treatment Named "New Treatment of the Year" by MyFaceMyBody Awards USA

Nov 12, 2018

WAYLAND, MASSACHUSETTS, NOVEMBER 12, 2018 – Candela Corporation, a leading global aesthetic device company, announces that the ProfoundÒ treatment has been named  “New Treatment of the Year” by The Global Aesthetic Awards, a leading aesthetic industry award, also known as MyFaceMyBody Awards USA. The Profound system is the only radiofrequency (RF) microneedling device that uses real-time temperature control to yield predictable outcomes and is FDA-cleared for the treatment of facial wrinkles and improvements in the appearance of cellulite[1].

The prestigious MyFaceMyBody Awards, now the largest and most highly recognized awards program globally, celebrates the innovation and customer excellence within the fast-growing aesthetics industry. The only industry awards dedicated to aesthetics, they honor leaders in aesthetics and brands for their product innovation and popularity.  Hundreds of applications from across the United States are received and category winners are elected from consumer and industry votes. 

“We are pleased to provide solutions for the treatments and outcomes consumers and the industry are seeking.  Over 3 million Americans had a nonsurgical aesthetic treatment in 2017[2] and this award is a testament to the growing demand for the Profound treatment’s clinically proven results and the patient satisfaction achieved with the device’s unique patented technology,” said Mary Trout, Chief Commercial Officer, Candela.  “The Profound treatment is clinically proven to create up to five times the elastin, twice the collagen and increased hyaluronic acid during nonsurgical treatment enabling practitioners to offer long lasting outcomes and provide their patients with a trusted, natural alternative to dermal injectables and surgery[3].”

The Profound system uses patented technology to deliver RF energy to induce the body’s natural healing response to regenerate new collagen, elastin and hyaluronic acid, without toxins or fillers. The real-time and continuously-monitored, temperature-controlled device allows practitioners to determine how much energy is delivered, as well as achieve and maintain a therapeutic temperature level, making this an extremely powerful solution to producing highly predictable results for the treatment of facial wrinkles. Additionally, the Profound system is the first and only FDA-cleared RF microneedling device that offers patients a long-term solution for improvement in the appearance of cellulite after just a single treatment.

“The Profound treatment provides an effective alternative to patients who may be considering surgery to treat facial wrinkles or the appearance of cellulite,” said Dr. Macrene Alexiades, a New York City-based Yale dermatologist.  “The Profound system stimulates all three skin components, collagen, elastin and hyaluronic acid, reducing the signs of aging and resulting in younger and smoother-looking skin in a single, nonsurgical treatment. This allows me to provide my patients with results they’re looking for, without the need for invasive surgery.”

For more information about the Profound® system, visit: https://syneron-candela.com/na/product/profound.  

To review the NewsWire release, visit: https://www.prnewswire.com/news-releases/profound

 

About Candela®
Candela is a leading global aesthetic device company with an extensive product portfolio and expansive global commercial footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, tattoo removal, women's health treatments, facial resurfacing, traumatic and surgical scar treatments, body contouring, improving the skin's appearance through the treatment of benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Candela has a wide portfolio of trusted, leading products, including Vbeam®, the Gentle Family®, CO2RE®, CO2RE Intima®, Profound®, elōs Plus®, PicoWay®, UltraShape®, VelaShape®, IPL and other laser-based platforms. Acquired by Apax Partners in July 2017, the Company markets, services and supports its products in 86 countries. It has offices in the United States, Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom and many international distributors.

Media Contact: 
EvolveMKD
P: 646.517.4220 | E: candela@evolvemkd.com

[1] 510(k) cleared K161043. Data on file.

[2] The American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank Statistics, 2017.

[3] Hantash BM, Ubeid AA, Chang H, Kafi R, Renton B. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Lasers Surg Med. 2009;41(1):1-9.

CONTACT
PATIENTS